Adagene Inc.

Equities

ADAG

US0053291078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-30 EDT			5-day change	1st Jan Change
2.595 ^USD	-1.70%		-6.99%	+34.36%

03-29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-29	Adagene Inc. Announces Board Changes	CI

Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.

April 28, 2023 at 07:01 am

From October 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 39,900 shares, representing 0.09% for $0.07 million under the buyback announced on June 29, 2022.

Latest news about Adagene Inc.

Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Adagene Inc. Announces Board Changes	03-29	CI
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board	03-07	CI
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4%	02-16	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	02-09	MT
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination	02-09	MT
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody	02-09	CI
ADRs End Higher; The9 Climbs 16%	01-19	DJ
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination	01-17	MT
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium	01-16	CI
ADRs End Lower; Aslan Pharmaceuticals Declines 38%	01-16	DJ
ADRs Slump, Grifols S.A. Declines 14.0%	01-11	DJ
ADRs Advance; Aslan Pharmaceuticals Climbs 27%	01-08	DJ
ADRs End Lower; Secoo Holding Declines 28%	12-20	DJ
ADRs Close Higher; Incannex Healthcare Inc. Climbs 723.7%	11-30	DJ
Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126	11-03	CI
ADRs Close Higher, Mobilicom Ltd. Climbs 41.4%	23-10-10	DJ
ADRs Advance, Akso Health Group Rises 29.6%	23-10-06	DJ
Adagene Inc. Announces Resignation of Fangyong Du as Chief Technology Officer	23-09-29	CI
Adagene Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Adagene Inc.'s Equity Buyback announced on June 29, 2022, has expired.	23-06-27	CI
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second Safebody® Novel Masked Antibody-Drug Conjugate	23-05-04	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.	23-04-28	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.	23-04-28	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.	23-04-28	CI

Chart Adagene Inc.

Duration

Period

More charts

Company Profile

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Companyâs main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.64 USD

Average target price

5 USD

Spread / Average Target

+89.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADAGENE INC.	+34.36%	117M
VERTEX PHARMACEUTICALS INCORPORATED	+8.92%	114B
REGENERON PHARMACEUTICALS, INC.	+10.48%	104B
ARGENX SE	-1.83%	22.57B
BIONTECH SE	-6.45%	22.5B
GENMAB A/S	-10.39%	17.95B
WUXI APPTEC CO., LTD.	-42.36%	16.48B
BEIGENE, LTD.	-14.45%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+3.76%	13.55B
SAREPTA THERAPEUTICS, INC.	+28.94%	10.99B

Bio Therapeutic Drugs